ClinicalTrials.gg
RecruitingNCT06805786Switch CGM T2DUpdated May 4, 2025

Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)

An observational study in Type 2 Diabetes, sponsored by LMC Diabetes & Endocrinology Ltd.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by LMC Diabetes & Endocrinology Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · LMC Diabetes & Endocrinology Ltd..

Started
2025
with 2 others
Observational
8 of 14
2 open now
Registered
10th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 10th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., or all of them as a file.
02

Study summary

The goal of this prospective study is to evaluate diabetes outcomes and patient experience following a switch from second generation intermittently scanned continuous glucose monitor (isCGM) to real-time continuous glucose monitor (rtCGM) compared with participants with continued isCGM use among adults with insulin-treated type 2 diabetes (T2D) in a specialist endocrinology clinic setting in Canada. The study aims include:

Primary outcome - Evaluate change in percent time in range (TIR) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with participants with continued second generation isCGM use.

Secondary outcomes - Compare glycemic and metabolic outcomes (ie. additional CGM metrics, HbA1c, and weight), and outcomes related to diabetes management (ie. self-reported hypoglycemia and change in total daily dose [TDD] of insulin) at 3-6 months follow-up in the rtCGM switch and isCGM cohorts among adults with insulin-treated T2D.

Exploratory outcomes - Evaluate patient-reported outcomes (PROs) in the rtCGM switch cohort only. PROs will include questions about device satisfaction and psychological distress at baseline and 3-6 months follow-up, and protocol-specific questions about Dexcom Care following use of the rtCGM device at 3-6 months follow-up. Additionally this study will compare percent TIR, percent TBR, percent TAR, and HbA1c between rtCGM switch and isCGM cohorts by insulin therapy subgroup (basal vs MDI therapy).

rtCGM switch participants will be enrolled at an LMC location and asked to complete PROs at baseline and 3-6 month follow-up. Continued isCGM participants will not be asked to complete PROs.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • type 2 diabetes
  • continuous glucose monitoring
  • HbA1c
  • time in range
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be adults, who are active patients with insulin-treated T2D at LMC, who switch from a FreeStyle Libre® 2 device to a Dexcom® G7 (rtCGM switch cohort) or initiated a FreeStyle Libre® 2 and maintain isCGM use (isCGM cohort) after December 2024

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Clinical diagnosis of T2D ≥ one year
  • Using insulin for ≥ 6 months
  • Continued FreeStyle Libre® 2 isCGM device (isCGM cohort) as of the study start date
  • Would like to switch from a FreeStyle Libre® 2 isCGM device to a Dexcom® G7 rtCGM device (rtCGM switch cohort) as of the study start date
  • Baseline ≥ 7.5%
  • Known rtCGM/isCGM start date (month and year)
  • Exclusive use of isCGM for ≥ 3 months
  • Data on LibreView platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date
  • ≥ 1 value for TIR (%) up to 6 months (± 6 weeks) prior to index date
  • ≥ 1 value for HbA1c (%) up to 6 months (± 6 weeks) prior to index date
  • Data consent

Exclusion criteria

Exclusion Criteria:

  • Have a prior history of rtCGM within 12 months of the index date
  • Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date
  • Recent or expectant titration of insulin dose ≥ 20% within 30 days of index date
  • Are pregnant at the time of study enrollment or intending to become pregnant during the study
  • Used the isCGM or rtCGM for \< 3 months
  • Using continuous subcutaneous insulin infusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Real-time continuous glucose monitoring switch group (rtCGM switch group)

    adults with insulin-treated T2D that are switching from an isCGM to an rtCGM

    Device: real-time continuous glucose monitor

  • intermittently scanned continuous glucose monitoring group (isCGM group)

    adults with insulin-treated T2D that are remaining on an isCGM for the whole study

Interventions

  • Devicereal-time continuous glucose monitor

    Individuals who switched from using isCGM to rtCGM

06

What researchers measure

Primary outcomes

  1. Change in Percent Time in Range (TIR)

    evaluate change in percent TIR (3.9 to 10.0 mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D. Percent TIR will be reported from the patient's EMR or Clarity® and LibreView® platforms (last 14 days of available data closest to the index date or 6-month follow-up date, where percent sensor capture is ≥ 70%).

    Time frame: from enrollment to 6 months follow up

Secondary outcomes

  1. Change in Percent Time Below Range (TBR)

    Evaluate change in percent TBR (\<3.9 mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  2. Change In Percent Time Below Range (TBR) in Level 2 Hypoglycemia

    Evaluate change in percent TBR in level 2 hypoglycemia (\<3.0 mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  3. Change in Percent Time Above Target Glucose Range (TAR)

    Evaluate change in percent TAR (\>10.0 mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  4. Change in Mean Glucose

    Evaluate change in mean glucose (mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  5. Change in Glycemic Variability measured as Standard Deviation of Glucose (mmol/L)

    Evaluate change in glycemic variability reported as standard deviation (SD) (mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  6. Change in Glycemic Variability measured as the Coefficient of Variation of Glucose (%)

    Evaluate change in glycemic variability reported as CV (%) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  7. Change in Frequency of Hypoglycemia Episodes

    Evaluate change in frequency of hypoglycemia episodes (frequency of events \<3.9 mmol/L) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  8. Percent Sensor Capture and Change in Percent Capture

    Evaluate Percent sensor capture and evaluate the change in percent sensor capture at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  9. Change in HbA1c

    Evaluate change in HbA1c (%) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  10. Portion of Participants Achieving HbA1c ≤7.0% at Follow-Up

    Evaluate portion of participants achieving HbA1c ≤ 7.0% at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  11. Change in Weight

    Evaluate change in weight (kg) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  12. Change in Weekly Incidence of Self-Reported Hypoglycemia

    Evaluate change in weekly incidence of self-reported hypoglycemia at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  13. Change in Proportion of Participants with ≥1 Self-reported Hypoglycemic Events per Week

    Evaluate change in proportion of participants with ≥1 self-reported hypoglycemic events per week at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  14. Change in Number of Non-Insulin Antihyperglycemic Agents (AHA)

    Evaluate change in number of non-insulin AHAs at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  15. Change in Total Daily Dose (TDD) of Insulin

    Evaluate change in total daily dose of insulin at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with continued second generation isCGM cohort among propensity score matched cohorts of adults with insulin-treated T2D.

    Time frame: from enrollment to 6 months follow up

  16. Number of rtCGM Discontinuations

    Evaluate the number of rtCGM discontinuations at 3-6 months follow-up only for the cohort switching from a second generation isCGM system to a rtCGM system.

    Time frame: from enrollment to 6 months follow up

Other outcomes

  1. Glucose Monitoring Device Satisfaction Scale (GMSS)

    includes questions about device satisfaction, filled out only by the cohort switching from isCGM to rtCGM

    Time frame: from enrollment to 6 months follow up

  2. Diabetes Distress Scale (DDS)

    includes questions about psychological distress , filled out only by the cohort switching from isCGM to rtCGM

    Time frame: from enrollment to 6 months follow up

  3. Protocol-Specific Dexcom Care Survey

    includes protocol-specific questions about rtCGM device, filled out only by the cohort switching from isCGM to rtCGM

    Time frame: assessed at 3-6 month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This is a real-world study using data retrieved from a national Diabetes Registry. IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2026, 17 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 17 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Feb 3, 2025
StartActual
Feb 11, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805786
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Collaborators
DexCom, Inc.
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Feb 11, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
May 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion